We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery (ESPECS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05558917
Recruitment Status : Enrolling by invitation
First Posted : September 28, 2022
Last Update Posted : September 28, 2022
Sponsor:
Information provided by (Responsible Party):
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria

Brief Summary:
The study aims to compare the efficacy of the two operating blocks PECS2 and ESP by measuring postoperative opioid consumption and, secondarily, to compare (between PECS and ESP) postoperative opioid consumption between surgery with/without axillary cavity dissection and with/without implantation of prosthesis or expansion

Condition or disease Intervention/treatment Phase
Breast Cancer Breast Neoplasms Breast Carcinoma Procedure: PECS BLOCK 2 Procedure: ESP BLOCK Not Applicable

Detailed Description:

Breast cancer is the most frequent type of cancer in the female population. Early detection is the most effective tool for improving prognosis, and the surgical approach plays a central role in the treatment of this disease. However, many are the psychophysical implications that patients face: among the main ones is postoperative and chronic pain, a symptom that greatly worsens the quality of life.

In the last decade it has been witnessed an important development of locoregional anesthesia techniques in all surgeries. In breast surgery, particularly mastectomy, the following locoregional anesthesia techniques are referred to as the Gold Standard:

  1. PVB (Paravertebral Block)
  2. PECS2 BLOCK (or modified PECS). For the same purposes, ESP Block (Erector Spinae Plane Block) has been applied experimentally, which has already shown its effectiveness in breast surgery in several trials.

By comparing postoperative opioid consumption between the two groups of patients, divided into PECS Block and ESP Block, the study aims to identify which anesthesia block is most effective in order to improve the care of patients undergoing mastectomy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery: Randomized Controlled Trial on Postoperatory Oppioid Consumption
Actual Study Start Date : September 7, 2022
Estimated Primary Completion Date : September 7, 2023
Estimated Study Completion Date : November 7, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: PECS BLOCK 2
PECS 2 (or modified PECS) is a block that involves the administration of local anesthetic under ultrasound guidance between the great pectoral and small pectoral and between the small pectoral and serratus anterior.
Procedure: PECS BLOCK 2
With the patient supine, the linear probe will be placed in the sagittal plane slightly lateral to the hemiclavicular line ipsilateral to the surgical site. Once both muscle planes of interest have been identified, in-plane needle insertion will proceed in the cranio-caudal direction. The first local anesthetic administration with Ropivacaine 0.5% will be 20ml between small pectoralis and serratus anterior. Coming out with the needle, 10ml of Ropivacaine 0.5% will then be injected between large and small pectoral.

Experimental: ESP BLOCK
ESP block is a block that involves injection of local anesthetic below the elevator muscles of the spine.
Procedure: ESP BLOCK
Positioning yourself behind the patient, lying on her side with the surgical hemilateral on top, you place the linear ultrasound probe in the sagittal plane and find the lateral margin of the transverse process. At this point, the blocking needle is inserted in the caudocranial direction and 25ml of Ropivacaine 0.5% is injected, taking care to visualize the anesthetic spread in the cranial direction.




Primary Outcome Measures :
  1. Morphine equivalent consumption in the postoperative 24h in simple mastectomies [ Time Frame: Postoperative 24 hours ]
    Morphine-equivalent consumption in the postoperative 24h that patients self-administer between the group of patients undergoing ESP and those undergoing PECS 2 in simple mastectomies.


Secondary Outcome Measures :
  1. Morphine-equivalent consumption in the postoperative 24h in mastectomies with axillary cavity emptying [ Time Frame: Postoperative 24 hours ]
    Morphine-equivalent consumption in the postoperative 24h that patients self-administer between the group of patients undergoing ESP and those undergoing PECS 2 in mastectomies with axillary cavity emptying.

  2. Morphine-equivalent consumption in the postoperative 24h in mastectomies with prosthesis or expander placement [ Time Frame: Postoperative 24 hours ]
    Consumption of morphine equivalents in the postoperative 24h that patients self-administer between the group of patients undergoing ESP and those undergoing PECS 2 in astecctomies with prosthesis or expander placement.

  3. Morphine-equivalent consumption in the postoperative 24h in mastectomies with axillary cavity emptying and implantation of prosthesis or expander [ Time Frame: Postoperative 24 hours ]
    Consumption of morphine equivalents in the postoperative 24h that patients self-administer between the group of patients undergoing ESP and those undergoing PECS 2 in mastectomies with axillary cavity emptying and implantation of prosthesis or expander

  4. PONV (Post Operating Nausea and Vomiting) [ Time Frame: Immediately after the surgery and at 2-4-8-12-24 hours after surgery ]
    Number of times the patient experienced nausea or vomiting

  5. Complications incidence [ Time Frame: Postoperative 24 hours ]
    Number of times the patient experienced complications such as bleeding or pneumothorax

  6. Time from end of surgery to first walk [ Time Frame: Postoperative 72 hours ]
    Time in hours

  7. Length of hospitalization [ Time Frame: Up to 7 days ]
    Lenght in days

  8. Patient's Likert Scale [ Time Frame: Postoperative 24 hours ]
    Patient satisfaction, from 1 - Strongly disagree to 5 - Strongly agree

  9. Surgeon's Likert scale [ Time Frame: Postoperative 24 hours ]
    Surgeon satisfaction, from 1 - Strongly disagree to 5 - Strongly agree



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing mastectomy exclusively for breast cancer
  • Presence of written informed consent to the trial

Exclusion Criteria:

  • Bilateral breast surgery
  • Previous drug use
  • Chronic opioid and minor opioid therapy
  • BMI >40
  • Allergy or contraindications to taking Paracetamol and Toradol
  • Inability to use PCA (Patient Controlled Analgesia)
  • Intraoperative opioid administration
  • Patients with neuropathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05558917


Locations
Layout table for location information
Italy
Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo
Alessandria, Piedmont, Italy, 15121
Sponsors and Collaborators
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Investigators
Layout table for investigator information
Principal Investigator: Mirco Leo, Physician Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo
Layout table for additonal information
Responsible Party: Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
ClinicalTrials.gov Identifier: NCT05558917    
Other Study ID Numbers: ASO.RianGen.22.02
First Posted: September 28, 2022    Key Record Dates
Last Update Posted: September 28, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria:
PECS2
ESP BLOCK
Breast Anesthesia
Mastectomy
Breast Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases